Pharmaceutics, Vol. 15, Pages 1664: Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review

Pharmaceutics, Vol. 15, Pages 1664: Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review

Pharmaceutics doi: 10.3390/pharmaceutics15061664

Authors: Akira Saito Joji Kitayama Ryozo Nagai Kenichi Aizawa

Despite remarkable recent progress in developing anti-cancer agents, outcomes of patients with solid tumors remain unsatisfactory. In general, anti-cancer drugs are systemically administered through peripheral veins and delivered throughout the body. The major problem with systemic chemotherapy is insufficient uptake of intravenous (IV) drugs by targeted tumor tissue. Although dose escalation and treatment intensification have been attempted in order to increase regional concentrations of anti-tumor drugs, these approaches have produced only marginal benefits in terms of patient outcomes, while often damaging healthy organs. To overcome this problem, local administration of anti-cancer agents can yield markedly higher drug concentrations in tumor tissue with less systemic toxicity. This strategy is most commonly used for liver and brain tumors, as well as pleural or peritoneal malignancies. Although the concept is theoretically reasonable, survival benefits are still limited. This review summarizes clinical results and problems and discusses future directions of regional cancer therapy with local administration of chemotherapeutants.